Shvartsburd, A; Sajadi, C; Morton, V; Mirabi, M; Gordon, J; Smith, RC (August 1984). “Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients”. Journal of Clinical Psychopharmacology4 (4): 194–198. doi:10.1097/00004714-198408000-00004. PMID6470190.
Purhonen, M; Koponen, H; Tiihonen, J; Tanskanen, A (November 2012). “Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort”. Pharmacoepidemiology and Drug Safety21 (11): 1227–1231. doi:10.1002/pds.3346. PMID22941581.
“Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin”. Clinical Pharmacology & Therapeutics59 (3): 322–31. (Mar 1996). doi:10.1016/S0009-9236(96)80010-5. PMID8653995.
Deetz, Thomas R., et al. (2003). “Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases”. Clinical infectious diseases37 (10): 1304-1312. doi:10.1086/379020.
Shvartsburd, A; Sajadi, C; Morton, V; Mirabi, M; Gordon, J; Smith, RC (August 1984). “Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients”. Journal of Clinical Psychopharmacology4 (4): 194–198. doi:10.1097/00004714-198408000-00004. PMID6470190.
Purhonen, M; Koponen, H; Tiihonen, J; Tanskanen, A (November 2012). “Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort”. Pharmacoepidemiology and Drug Safety21 (11): 1227–1231. doi:10.1002/pds.3346. PMID22941581.
“Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin”. Clinical Pharmacology & Therapeutics59 (3): 322–31. (Mar 1996). doi:10.1016/S0009-9236(96)80010-5. PMID8653995.